FRANKFURT – On Friday, Sanofi (NASDAQ: SNY) said that its multiple sclerosis drug candidate was shown to delay the worsening of a progressive form of the disease by 31%, as the French drugmaker eyes a request for approval later this year.
Earlier this month, the company said in a brief summary that the late-stage trial with the drug candidate tolebrutinib was successful. That mitigated a setback announced at the same time that trials on a more common relapsing form of the disease had failed.
Sanofi is pursuing several opportunities in MS, a debilitating nerve disease, to offset revenue losses after the recent end of MS pill Aubagio’s patent protection, part of a push to become a powerhouse in anti-inflammatory drugs.
CEO Paul Hudson has made progress in regaining investor confidence in the pharma pipeline since he unexpectedly abandoned 2025 margin targets last October to boost drug development spending.
Tolebrutinib, from the $3.7 billion takeover of Principia in 2020, belongs to a class of compounds known as Bruton’s tyrosine kinase (BTK) inhibitors, which has also attracted Novartis (NYSE: NVS) and Roche.
They are designed to selectively block the harmful autoimmune reaction behind MS for a more targeted approach than standard immunosuppressant drugs.
However, investors have been kept on edge over revenue prospects because of a possible link of BTK inhibitors to liver damage and uncertain efficacy.
Sanofi (NASDAQ: SNY) said frequent monitoring during trials had mitigated serious liver problems.
(Source: Reuters)
Edward Cooke is a financial analyst, freelance writer, and editor. He has six years of experience in financial journalism. He has an in-depth understanding of equities markets, tracking major indices and providing real-time analysis on stock price movements, corporate earnings, and market sentiment.
